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Abstract 
Short Communication on TGM2, with data on 
DNA/RNA, on the protein encoded and where the 
gene is implicated. 
Identity 
Other names: G-ALPHA-h, GNAH, TG2, TGC 
HGNC (Hugo): TGM2 
Location: 20q11.23 
DNA/RNA 
Description 
The gene encompasses 36838bp; 13 exons; a dense 
CpG island engulfs exon 1 and the transcriptional 
start site; negative strand. 
Transcription 
Two transcript variants 1) 3937bp; 2) 2326bp (C-
terminal truncation exons 11-13); induced by 
NFkB, retinoic acid, IL-6, TGF-beta1, HRE, AP-1 
and GRE. 
Protein 
Description 
687 amino acids; 78 kilodaltons; monomer. 
Expression 
Ubiquitously expressed. 
Localisation 
Mostly intracellular (cytosol, nucleus and cell 
membrane); extracellular. 
Function 
Multifunctional enzyme with transglutaminase 
crosslinking activity (catalyze covalant bonds 
between the ε-amino group of a lysine and the γ-
carboxyl group of a glutamine residue) stabilizing 
the extracellular matrix (ECM) and cell-ECM 
interaction; require Ca2+ for catalytic activity; 
inhibited by GTP; under stress (loss of Ca2+) may 
play a role in apoptosis; involved in wound healing 
and inflammation; aberrent overexpression of TG2 
is linked to chemotherapeutic drug resistance. 
Mutations 
Germinal 
No germinal mutations have been identified; low 
frequency of SNPs. 
Somatic 
No somatic mutations have been identified in 
cancer; can be transcriptionally silenced by CpG 
methylation in cancer (breast and brain); 
overexpression in many cancers; 3 missense 
mutations identified in early-onset type 2 diabetes 
patients (c.989T>G, c.992T>A, c.998A>G). 
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Implicated in 
Breast cancer 
Oncogenesis 
Overexpression renders culture mammary epithelial 
cells resistant to doxorubicin, associated with 
invasive phenotype and epithelial-to-mesenchymal 
transition; epigenetic silencing has been 
documented in many breast cancer cell lines and 
patient samples. In 30 patients, TG2 overexpression 
was found more often in lymph node metastases 
than primary tumors. 
Ovarian cancer 
Prognosis 
Overexpression of TG2 is associated with negative 
survival in 93 patients (p=0.007). 
Oncogenesis 
Overexpression renders ovarian cancer cells 
resistant to cisplatin and is associated with higher 
tumor stage. 
Pancreatic cancer 
Prognosis 
Overall survival of stage II pancreatic ductal 
adenocarcinoma (PDAC) patients with TG2-
mediated loss of PTEN was poor (20.7 months) 
compared to 68.6 months for TG2 negative and 
PTEN positive patients. 
Oncogenesis 
Overexpression; resistance to gemcitabine; in 51 
PDAC tumor samples overexpression of TG2 was 
associated with loss of PTEN expression. 
Non-small cell lung cancer (NSCLC) 
Prognosis 
In 429 Korean patients, TG2 expression was 
associated with shorter disease free survival and 
correlated with recurrence. 
Oncogenesis 
Overexpression ; cisplatin resistance. 
Celiac disease 
Autoantibodies against TG2; autoantibodies are 
deposited in the small-bowl mucosa; TG2 
crosslinks gliadin peptides (gluten) derived. 
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